Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes"
DOI: 10.1111/dom.15045
Abstract: Real‐world data are required to support glucagon‐like peptide‐1 receptor agonist use in type 2 diabetes (T2D). SURE France assessed once‐weekly semaglutide in adults with T2D in real‐world clinical practice. read more here.
Keywords: sure france; type diabetes; semaglutide use; weekly semaglutide ... See more keywords